170 related articles for article (PubMed ID: 24365641)
21. Infliximab or biosimilars in sarcoidosis; to switch or not to switch?
Veltkamp M; Drent M; Baughman RP
Sarcoidosis Vasc Diffuse Lung Dis; 2016 Jan; 32(4):280-3. PubMed ID: 26847093
[No Abstract] [Full Text] [Related]
22. An update on biosimilar drugs for inflammatory bowel disease.
Schreiber S
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():1-3. PubMed ID: 26395529
[TBL] [Abstract][Full Text] [Related]
23. Biosimilars in dermatology: starting with infliximab.
Puig L
Actas Dermosifiliogr; 2013 Apr; 104(3):175-80. PubMed ID: 23218608
[No Abstract] [Full Text] [Related]
24. Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations.
Peyrin-Biroulet L; Lönnfors S; Roblin X; Danese S; Avedano L
J Crohns Colitis; 2017 Jan; 11(1):128-133. PubMed ID: 27481878
[TBL] [Abstract][Full Text] [Related]
25. Biosimilars in rheumatology: perspective and concerns.
Scheinberg MA; Azevedo VF
Rheumatology (Oxford); 2014 Mar; 53(3):389-90. PubMed ID: 23878310
[No Abstract] [Full Text] [Related]
26. Biosimilars in the therapy of inflammatory bowel diseases.
Hlavaty T; Letkovsky J
Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
[TBL] [Abstract][Full Text] [Related]
27. [First biosimilar infliximab approved].
Neumaier J
MMW Fortschr Med; 2015 Mar; 157 Suppl 1():88. PubMed ID: 26013000
[No Abstract] [Full Text] [Related]
28. Biosimilars versus biologics for inflammatory conditions.
Perry D; Ton J; Kolber MR
Can Fam Physician; 2019 Sep; 65(9):636. PubMed ID: 31515313
[No Abstract] [Full Text] [Related]
29. Of patents and patent disputes: The TNFα patent files. Part 1: Humira.
Storz U
Hum Antibodies; 2017; 25(1-2):1-16. PubMed ID: 27792008
[TBL] [Abstract][Full Text] [Related]
30. Taming TNF: strategies to restrain this proinflammatory cytokine.
Eigler A; Sinha B; Hartmann G; Endres S
Immunol Today; 1997 Oct; 18(10):487-92. PubMed ID: 9357141
[TBL] [Abstract][Full Text] [Related]
31. Biologic Therapy in Crohn's Disease-What We Have Learnt So Far.
Majchrzak K; Fichna J
Curr Drug Targets; 2020; 21(8):792-806. PubMed ID: 31854272
[TBL] [Abstract][Full Text] [Related]
32. Adalimumab: new indication. Severe Crohn's disease: a second TNF alpha antagonist, subcutaneous administration.
Prescrire Int; 2008 Aug; 17(96):137. PubMed ID: 19480092
[No Abstract] [Full Text] [Related]
33. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
Jahnsen J; Detlie TE; Vatn S; Ricanek P
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
[TBL] [Abstract][Full Text] [Related]
34. Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes.
Raza A
Microsc Res Tech; 2000 Aug; 50(3):229-35. PubMed ID: 10891888
[TBL] [Abstract][Full Text] [Related]
35. Inflammatory diseases: Integrating biosimilars into clinical practice.
Feldman SR
Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S16-21. PubMed ID: 26058549
[TBL] [Abstract][Full Text] [Related]
36. "Total evidence" network meta-analysis as a tool for improving the assessment of biosimilars: application to etanercept in rheumatoid arthritis
.
Messori A; Trippoli S; Marinai C
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):517-520. PubMed ID: 28372634
[TBL] [Abstract][Full Text] [Related]
37. Treatment preferences of originator versus biosimilar drugs in Crohn's disease; discrete choice experiment among gastroenterologists.
Baji P; Gulácsi L; Lovász BD; Golovics PA; Brodszky V; Péntek M; Rencz F; Lakatos PL
Scand J Gastroenterol; 2016 Jan; 51(1):22-7. PubMed ID: 26059967
[TBL] [Abstract][Full Text] [Related]
38. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
[TBL] [Abstract][Full Text] [Related]
39. New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.
Thill M
Expert Rev Anticancer Ther; 2015 Mar; 15(3):331-8. PubMed ID: 25539719
[TBL] [Abstract][Full Text] [Related]
40. Anti-TNF Therapy.
Udalova I; Monaco C; Nanchahal J; Feldmann M
Microbiol Spectr; 2016 Aug; 4(4):. PubMed ID: 27726761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
